XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborations and Other Arrangements (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue $ 6,740,100,000 $ 5,499,400,000 $ 13,545,700,000 $ 11,359,200,000  
Contract liabilities 270,900,000   270,900,000   $ 276,800,000
China          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 522,500,000 239,800,000 884,700,000 507,100,000  
Outside U.S.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 3,035,900,000 2,354,600,000 5,900,200,000 4,885,600,000  
Jardiance          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 356,500,000 262,000,000.0 668,500,000 529,500,000  
Jardiance | Outside U.S.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 162,100,000 116,900,000 322,900,000 239,800,000  
Trajenta          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 89,200,000 76,800,000 183,800,000 170,000,000.0  
Basaglar          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 210,700,000 290,400,000 457,300,000 594,100,000  
Basaglar | Outside U.S.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 77,300,000 60,700,000 148,700,000 134,000,000.0  
Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 208,400,000 145,000,000.0 402,200,000 284,700,000  
Olumiant® | Outside U.S.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 190,600,000 131,800,000 359,700,000 260,200,000  
COVID-19 Antibodies          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 148,900,000 0 959,100,000 0  
COVID-19 Antibodies | Outside U.S.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 65,700,000 0 225,100,000 0  
Tyvyt®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 105,000,000.0 64,100,000 214,600,000 121,500,000  
Tyvyt® | Outside U.S.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 105,000,000.0 $ 64,100,000 214,600,000 $ 121,500,000  
Tanezumab | Outside US And Japan          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, rights and obligations, terms, annual net sales threshold (up to) 150,000,000.0   150,000,000.0    
Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Contract liabilities 20,100,000   20,100,000   29,700,000
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 146,200,000   146,200,000   156,200,000
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 101,600,000   101,600,000   114,600,000
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized (158,600,000)   $ (158,600,000)   $ (168,000,000.0)
Royalty Agreement Terms | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, rights and obligations, percentage (up to)     20.00%    
Milestone Payments, Capitalized as Intangible Assets | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 60,000,000.0   $ 60,000,000.0    
Milestone Payments, Capitalized as Intangible Assets | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 210,000,000.0   210,000,000.0    
Milestone Payments, Capitalized as Intangible Assets | Tyvyt®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 40,000,000.0   40,000,000.0    
Milestone Payments, Development and Regulatory | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 100,000,000.0   100,000,000.0    
Milestone Payments, Development and Regulatory | Tanezumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 147,500,000   147,500,000    
Milestone Payments, Development and Regulatory | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 85,000,000.0   85,000,000.0    
Milestone Payments, Sales-based | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 120,000,000.0   120,000,000.0    
Milestone Payments, Sales-based | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 150,000,000.0   150,000,000.0    
Milestone Payments, Sales-based | Tanezumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 1,230,000,000   1,230,000,000    
Milestone Payments, Sales-based | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 1,250,000,000   1,250,000,000    
Milestone Payments, Success-based Regulatory | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 15,000,000.0   15,000,000.0    
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | Non-CHINA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 825,000,000.0   825,000,000.0    
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | China          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 195,000,000.0   195,000,000.0    
Roche | Milestone Payments, Development and Regulatory | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized 180,000,000.0   180,000,000.0    
Roche | Milestone Payments, Sales-based | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones capitalized $ 1,030,000,000.00   $ 1,030,000,000.00